Search - tctmd.com

Displaying 701 - 720 of 2735

Sort: Relevancy | Date

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis With Few Complications

Michael O'Riordan

June 23, 2018

News Conference News The Structural Heart Disease Summit 2018

PORTICO I Postapproval Registry Outside the US Offers ‘Teaser’ for Pivotal Trial

Shelley Wood

June 23, 2018

News Conference News The Structural Heart Disease Summit 2018

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Michael O'Riordan

June 22, 2018

News Conference News The Structural Heart Disease Summit 2018

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

Shelley Wood

June 21, 2018

News Conference News The Structural Heart Disease Summit 2018

Nearly 25% of AVR Patients Experience Anxiety or Depression in First Year

Michael O'Riordan

June 21, 2018

News Daily News

‘Failure to Rescue’ Doesn’t Fully Explain Higher Mortality at Lower-Volume TAVR Centers

Yael L. Maxwell

June 20, 2018

Presentation

Failure to Rescue, Hospital Volume, and In-Hospital Mortality After TAVR

June 20, 2018

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

News Daily News

Burden of Anticoagulation Can Be Reduced in Some Patients With Mechanical Valves

L.A. McKeown

June 12, 2018

Presentation EuroPCR 2018

Real World Outcomes of TAVR with the SAPIEN-3 Valve in Intermediate Risk Patients: Comparison of Data from the TVT Registry with PARTNER S3 Studies

Presenter: E. Murat Tuzcu

May 25, 2018

Presentation EuroPCR 2018

Longevity of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients with Severe Aortic Stenosis and Lower Surgical Risk

Presenter: Lars Sondergaard

May 25, 2018

News Conference News EuroPCR 2018

Real-World Sapien 3 Results Match Trial Experience in Intermediate-Risk Patients

Caitlin E. Cox

May 25, 2018

News Conference News EuroPCR 2018

NOTION: TAVR in Low-Risk Patients Maintains Its Momentum Through 6 Years

Caitlin E. Cox

May 24, 2018

News Conference News EuroPCR 2018

Embolic Protection in TAVR: Signs of Benefit, but Road Map for Use Still Uncharted

Caitlin E. Cox

May 23, 2018

Presentation

Causes and Associated Costs of 30-Day Readmission of TAVR vs SAVR in the US

May 11, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2018

Caitlin E. Cox

April 30, 2018

Presentation SCAI 2018

Cerebral Embolic Protection: Protect Everyone

Presenter: Samir Kapadia

April 28, 2018

Presentation SCAI 2018

Unresolved Issues: Cerebral Embolic Protection Use Selectively!

Presenter: Steven J Yakubov

April 28, 2018

News Conference News SCAI 2018

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

Shelley Wood

April 28, 2018

News Conference News SCAI 2018

Longer Hospital Stays After TAVR Associated With Worse Outcomes

L.A. McKeown

April 27, 2018

Advertisement

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis With Few Complications

PORTICO I Postapproval Registry Outside the US Offers ‘Teaser’ for Pivotal Trial

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

Nearly 25% of AVR Patients Experience Anxiety or Depression in First Year

‘Failure to Rescue’ Doesn’t Fully Explain Higher Mortality at Lower-Volume TAVR Centers

Failure to Rescue, Hospital Volume, and In-Hospital Mortality After TAVR

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Burden of Anticoagulation Can Be Reduced in Some Patients With Mechanical Valves

Real World Outcomes of TAVR with the SAPIEN-3 Valve in Intermediate Risk Patients: Comparison of Data from the TVT Registry with PARTNER S3 Studies

Longevity of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients with Severe Aortic Stenosis and Lower Surgical Risk

Real-World Sapien 3 Results Match Trial Experience in Intermediate-Risk Patients

NOTION: TAVR in Low-Risk Patients Maintains Its Momentum Through 6 Years

Embolic Protection in TAVR: Signs of Benefit, but Road Map for Use Still Uncharted

Causes and Associated Costs of 30-Day Readmission of TAVR vs SAVR in the US

TCTMD’s Top 10 Most Popular Stories for April 2018

Cerebral Embolic Protection: Protect Everyone

Unresolved Issues: Cerebral Embolic Protection Use Selectively!

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

Longer Hospital Stays After TAVR Associated With Worse Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content